Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

被引：0
|
作者：
Francesco Gelsomino
Marcello Tiseo
Fausto Barbieri
Ferdinando Riccardi
Luigi Cavanna
Antonio Frassoldati
Angelo Delmonte
Lucia Longo
Claudio Dazzi
Saverio Cinieri
Ida Colantonio
Francesca Sperandi
Giuseppe Lamberti
Stefano Brocchi
Lorenzo Tofani
Luca Boni
Andrea Ardizzoni
机构：
[1] Policlinico Sant’Orsola-Malpighi,Medical Oncology Unit
[2] Azienda Ospedaliero-Universitaria of Parma,Medical Oncology Unit
[3] Policlinico of Modena,Medical Oncology Unit
[4] Azienda Ospedaliera Cardarelli,Medical Oncology Unit
[5] AUSL of Piacenza,Medical Oncology Unit
[6] Azienda Ospedaliero-Universitaria of Ferrara,Medical Oncology Unit
[7] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS,Department of Medical Oncology
[8] AUSL of Modena,Medical Oncology Unit
[9] Hospital of Carpi,Medical Oncology Unit
[10] AUSL of Romagna,Medical Oncology Unit
[11] Hospital of Ravenna,Medical Oncology Unit
[12] Hospital of Brindisi,Radiology Unit
[13] Hospital of Cuneo,Clinical Trial Center, Istituto Toscano Tumori
[14] Policlinico Sant’Orsola-Malpighi,undefined
[15] Azienda Ospedaliero-Universitaria Careggi,undefined
来源：
British Journal of Cancer | 2020年 / 123卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：26 / 32
页数：6
相关论文
共 50 条
  • [31] A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
    Kim, Yu-Jung
    Keam, Bhumsuk
    Ock, Chan-Young
    Song, Sanghoon
    Kim, Miso
    Kim, Se Hyun
    Kim, Ki Hwan
    Kim, Jin-Soo
    Kim, Tae Min
    Kim, Dong-Wan
    Lee, Jong Seok
    Heo, Dae Seog
    LUNG CANCER, 2019, 136 : 122 - 128
  • [32] A phase I/II trial of combination nab-paclitaxel and nintedanib or nab-paclitaxel and placebo in relapsed NSCLC adenocarcinoma (N3)
    Tokaca, N.
    Espinasse, A.
    Petruckevitch, A.
    Ellis, S.
    Yousaf, N.
    Bhosle, J.
    O'Brien, M.
    Popat, S.
    LUNG CANCER, 2017, 103 : S77 - S78
  • [33] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion
    Tamiya, Motohiro
    Tamiya, Akihiro
    Suzuki, Hidekazu
    Taniguchi, Yoshihiko
    Katayama, Kanako
    Minomo, Shojiro
    Nakao, Keiko
    Takeuchi, Naoko
    Matsuda, Yoshinobu
    Naito, Yujiro
    Shiroyama, Takayuki
    Okamoto, Norio
    Okishio, Kyoichi
    Kumagai, Toru
    Atagi, Shinji
    Imamura, Fumio
    Hirashima, Tomonori
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1106 - 1112
  • [34] Phase II Trial of Weekly Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: KTOSG Trial 1301
    Sakata, Shinya
    Saeki, Sho
    Okamoto, Isamu
    Otsubo, Kohei
    Komiya, Kazutoshi
    Morinaga, Ryotaro
    Yoneshima, Yasuto
    Koga, Yuichiro
    Enokizu, Aimi
    Kishi, Hiroto
    Hirosako, Susumu
    Yamaguchi, Emi
    Aragane, Naoko
    Fujii, Shinji
    Harada, Taishi
    Iwama, Eiji
    Nakanishi, Yoichi
    Kohrogi, Hirotsugu
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S923 - S923
  • [35] Phase II study of nab-paclitaxel plus carboplatin for patients with non-small-cell lung cancer and interstitial lung disease
    Kenmotsu, Hirotsugu
    Yoh, Kiyotaka
    Mori, Keita
    Ono, Akira
    Baba, Tomohisa
    Fujiwara, Yutaka
    Yamaguchi, Ou
    Ko, Ryo
    Okamoto, Hiroaki
    Yamamoto, Nobuyuki
    Ninomiya, Takashi
    Ogura, Takashi
    Kato, Terufumi
    CANCER SCIENCE, 2019, 110 (12) : 3738 - 3745
  • [36] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
    Motohiro Tamiya
    Akihiro Tamiya
    Hidekazu Suzuki
    Yoshihiko Taniguchi
    Kanako Katayama
    Shojiro Minomo
    Keiko Nakao
    Naoko Takeuchi
    Yoshinobu Matsuda
    Yujiro Naito
    Takayuki Shiroyama
    Norio Okamoto
    Kyoichi Okishio
    Toru Kumagai
    Shinji Atagi
    Fumio Imamura
    Tomonori Hirashima
    Investigational New Drugs, 2021, 39 : 1106 - 1112
  • [37] nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer
    Hirsh, Vera
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (02) : 129 - 141
  • [38] A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer: Results of NICE Salvage Study
    Kogure, Y.
    Niwa, T.
    Yoshioka, H.
    Saka, H.
    Hata, A.
    Katakami, N.
    Ozawa, Y.
    Matsuo, N.
    Hoshino, T.
    Wakuda, K.
    Kenmotsu, H.
    Takahashi, T.
    Nosaki, K.
    Takenoyama, M.
    Tajima, M.
    Takahashi, K.
    Ando, M.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S355 - S356
  • [39] Effectiveness of nab-paclitaxel for malignant effusion in non-small cell lung cancer
    Iwai, Y.
    Koyama, N.
    Watanabe, Y.
    Miwa, C.
    Nagai, Y.
    Koyama, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer
    Hirose, Takashi
    Nakashima, Masanao
    Shirai, Takao
    Kusumoto, Sojiro
    Sugiyama, Tomohide
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Ohnishi, Tsukasa
    Ohmori, Tohru
    Adachi, Mitsuru
    LUNG CANCER, 2011, 73 (03) : 345 - 350
12345